GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BGI Genomics Co Ltd (SZSE:300676) » Definitions » Construction In Progress

BGI Genomics Co (SZSE:300676) Construction In Progress : ¥407 Mil (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is BGI Genomics Co Construction In Progress?

BGI Genomics Co's quarterly construction in progress declined from Sep. 2023 (¥1,490 Mil) to Dec. 2023 (¥418 Mil) and declined from Dec. 2023 (¥418 Mil) to Mar. 2024 (¥407 Mil).

BGI Genomics Co's annual construction in progress increased from Dec. 2021 (¥38 Mil) to Dec. 2022 (¥752 Mil) but then declined from Dec. 2022 (¥752 Mil) to Dec. 2023 (¥418 Mil).


BGI Genomics Co Construction In Progress Historical Data

The historical data trend for BGI Genomics Co's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BGI Genomics Co Construction In Progress Chart

BGI Genomics Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 184.54 53.40 38.50 752.33 418.09

BGI Genomics Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 815.44 1,340.85 1,489.97 418.09 407.01

BGI Genomics Co Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


BGI Genomics Co (SZSE:300676) Business Description

Traded in Other Exchanges
N/A
Address
21 Hongan Third Street, Dong, Huada Complex Park, Yantian District, Shenzhen, CHN, 518083
BGI Genomics Co Ltd is a China-based company principally engaged in the provision of genomic class diagnosis and research services through the application of biotechnology. It offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company mainly provides services for domestic and overseas academic institutions hospitals, medical institutions and others.
Executives
Wang Jian Director
Liu Na Executives
Sun Ying Jun Director
Yin Ye Directors, executives
Du Yu Tao Directors, executives
Li Song Gang Supervisors
Hu Yu Jie Supervisors
Xu Qian Secretary Dong
Li Zhi Ping Executives
Chen Yi Qing Executives
Li Wen Qi Supervisors

BGI Genomics Co (SZSE:300676) Headlines

No Headlines